NanoViricides, Inc. (NNVC) Says Ebola Phase IIA Is Progressing
NanoViricides said its Phase IIA trial of NV-387 oral gummies for Ebola Bundibugyo in DRC is progressing and enrolling, focused on safety/tolerability with up to 20 subjects and adaptive dosing over 6—12 days; efficacy signals may be explored but not powered.Material DetailsContext by AI AnalystThi…